Pamela Pavco - RXi Pharmaceuticals Insider

RXi Pharmaceuticals Corporation -- USA Stock  

USD 4.61  0.78  14.47%

Chief Devel. Officer

Ms. Pamela Pavco, Ph.D. is a Chief Development Officer of RXI Pharmaceuticals Corporationrationration. Prior to this, Dr. Pavco served as our Senior Vice President of Pharmaceutical Development from September 24, 2011 until April 2012. From March 2007 to September 24, 2011, she served as the Vice President of Pharmaceutical Development of Galena Biopharma, Inc. Dr. Pavco has over 20 years of research and development experience in oligonucleotides. Dr. Pavco was Senior Director, Research and Development Project Management at Sirna Therapeutics, Inc., from 2002 until 2006, when it was acquired by Merck Co., Inc. for 1.1 billion. While at Sirna, she was responsible for the discovery research and development of Sirna027, the first chemically modified siRNA to enter clinical trials. Dr. Pavco also managed Sirnas alliance with Allergan, Inc. that was initiated to continue discovery research in the area of ophthalmology and take Sirna027 forward into Phase 2 clinical studies. While at Sirna, Dr. Pavco served in various additional capacities, including Director of Biology Research and Director of Pharmacology and she also managed numerous corporate collaborations and internal programs focusing on the development of therapeutic oligonucleotides in the fields of oncology, antiangiogenesis, hepatitis, respiratory disease and Huntingtons disease. Dr. Pavco has authored numerous scientific articles and contributed to approximately 58 patents and patent applications in the oligonucleotide therapeutics field
Age: 57  Executive Since 2012  Ph.D    
Pavco received a Ph.D. in Biochemistry from Virginia Commonwealth University in 1983 and did her postdoctoral work at Duke University. She is a member of the American Association of Cancer Research and the Association for Research and Vision in Ophthalmology.

Management Efficiency

The company has return on total asset (ROA) of (111.05) % which means that it has lost $111.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (395.58) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Found 12 records


Eric CrombezDimension Therapeutics Inc
Ayelet HornVascular Biogenics Ltd
Sonja NelsonNantKwest Inc
David AndersonVBI Vaccines Inc
Mary ThistleDimension Therapeutics Inc
Samuel WadsworthDimension Therapeutics Inc
Rishi GuptaDimension Therapeutics Inc
Eric MDDimension Therapeutics Inc
Shayla ForsterVBI Vaccines Inc
Sam WadsworthDimension Therapeutics Inc
Carole HoDenali Therapeutics Inc
Jacob GeorgeVascular Biogenics Ltd

Entity Summary

RXi Pharmaceuticals Corporation, a clinical-stage company, focuses on developing therapeutics for unmet medical needs. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. RXi Pharmaceuticals operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 15 people.RXi Pharmaceuticals Corporation (RXII) is traded on Nasdaq Capital Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 15 people. RXi Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add RXi Pharmaceuticals Corporation to your portfolio

Top Management

RXi Pharmaceuticals Leadership Team
Geert Cauwenbergh, CEO, Ph.D
Robert Bitterman, Director, MBA
Pamela Pavco, Executive, Ph.D
Keith Brownlie, Director
Jonathan Freeman, Director, MBA
Gerrit Dispersyn, Executive
Curtis Lockshin, Director, Ph.D
Paul Dorman, Director
Alexey Eliseev, Executive
Tamara McGrillen, Executive

Stock Performance

RXi Pharmaceuticals Performance Indicators